Hemosphere, a medical technology company, has appointed Patrick Wethington as its new chief executive officer (CEO), effective immediately. Mr Wethington succeeds Doris Engibous, former president and CEO of the company.
Reportedly, before joining Hemosphere, Mr Wethington served as global vice president of sales and marketing at Gambro, formerly CHF Solutions, where he oversaw the successful commercialisation of CHF’s Aquapheresis Peripheral Ultrafiltration System.
Prior to Gambro, Mr Wethington spent 10 years in various sales and marketing leadership positions at St Jude Medical Endocardial Solutions. He started his career with CPI Guidant, part of Boston Scientific, where he held numerous clinical, product development and brand management roles.
Hemosphere also reported that Edson Spencer of Affinity Capital Management has taken on the position of lead director for Hemosphere’s board. Mr Spencer has served on the company’s board for two years.
Mr Wethington said: “Hemosphere is an exciting company with an impressive history of innovation. I’m honored to join Hemosphere’s talented team. I look forward to leveraging my background and experience to help further establish the HeRO device as the next standard of care for maintaining long-term access for hemodialysis patients with venous outflow obstruction.”
Mr Spencer said: “On behalf of our board, I want to thank Doris for her five and a half years of service. Doris successfully led the company through FDA clearance and early commercialization of Hemosphere’s HeRO Vascular Access Device, and she decided now is the appropriate time for different leadership. We wish Doris the best in her future endeavors.
“Pat brings the experience and skill set to build on Doris’ achievements and continue HeRO’s commercialization success. We will benefit from Pat’s extensive medical device background, commercialization experience and demonstrated leadership qualities.”